Cell line · CVCL_4401
Papers49
8 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 49
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MORC3 represses a tandem repeat enhancer to regulate interferon. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Rab14 regulates the transport of human papillomavirus to the trans-Golgi network for infectious cell entry. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways. | Oncol Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Real-Time Visualization of Isoform-Specific RAF-KRAS Interactions in Living Cells Using FRET-BRET Hybrid Biosensors. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR screen of human pancreatic cancer xenografts identifies a KLF5 proliferation vulnerability through epigenetic modifiers NCAPD2 and MTHFD1. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dissection of Gαs and Hedgehog Signaling Cross-talk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression. | Mol Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SLC25A45 is required for mitochondrial uptake of methylated amino acids and de novo carnitine biosynthesis. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| T cell cholesterol transport links intestinal immune responses to dietary lipid absorption. | Science | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Model-guided design of microRNA-based gene circuits supports precise dosage of transgenic cargoes into diverse primary cells. | Cell Syst | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Aberrant expression of nuclear prothymosin α contributes to epithelial-mesenchymal transition in lung cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| RBM43 controls PGC1α translation and a PGC1α-STING signaling axis. | Cell Metab | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathway. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The mevalonate pathway contributes to breast primary tumorigenesis and lung metastasis. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Long non-coding RNA GRASLND links melanoma differentiation and interferon-gamma response. | Front Mol Biosci | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_4401/papers